181 research outputs found

    Determination of the laser-induced damage threshold of polymer optical fibers

    Get PDF
    Investigating the properties of manufactured polymer optical fibers is essential to determine proper areas of application. Using pulsed laser radiation, especially with respect to laser activity in optical fibers, the maximum acceptable transmittable energy without inducing damage is of particular interest. Therefore, this work is related to laser-induced damage in polymer optical fibers at a wavelength of 532 nm and a pulse duration of 7.3 ns. In particular, the influence of the coupling condition on the transmittable pulse energy and the damage behavior applying an R-on-1 test procedure are analyzed in this study. The obtained results give information about the long-Term behavior and will be used to optimize the manufacturing process. © COPYRIGHT SPI

    Laser-induced degradation and damage morphology in polymer optical fibers

    Get PDF
    The radiation of pulsed laser systems can generate changes in various materials. On the one hand, these modifications can be used for a variety of applications i.e. laser welding, cutting and many more [1]. The precision and quality depends on the material and laser parameters. On the other hand, material changes are not always desired in other applications. When using optical materials such as optical fibers as a light guide or as a sensor, laser-induced damage effects inside the fiber are to be prevented to ensure constant light guidance and the reliable monitoring of a desired parameter. Therefore, investigations for quality assurance need to be performed. For this reason, this work investigates laserinduced damage in polymer optical fibers (POF) using a nanosecond pulsed laser system at a wavelength of 532 nm. The impact of different laser and fiber parameters on the long-term degradation behavior is observed. In addition, the overall degradation behavior as well as the knowledge gained by analyzing the damage morphology and distribution will be used to obtain a better understanding of the damage mechanisms

    Coming Full Circle: Reflections and Inspirations from a Cystic Fibrosis Patient Scientist Panel

    Get PDF
    Care for many progressive chronic diseases continues to improve, allowing patients to survive and thrive for longer periods of time1. People living with such conditions may now find themselves able to achieve long-term goals in education and career development2. Many people now occupy the dual roles of scientist and patient3. This commentary article synthesizes experiences of scientists and advocates with the progressive genetic disease cystic fibrosis (CF) who collaborated on a career development session for the Cystic Fibrosis Foundation’s inaugural ResearchCon event in 2019. It explores how such collaborations affirm and transform individual perspectives on patient science and its importance in broader scientific research agenda setting. We first share our own individual insights about the experience and impact of the ResearchCon panel session before progressing to discussion and future directions centering the shared insights from one another’s reflections

    Intensive laparoscopic laparoscopic training in live tissues – 11 years of experience in Pius Branzeu center from timisoara, Romania

    Get PDF
    Surgical Clinic II , University of Medicine and Pharmacy Timisoara, Romania, Al XI-lea Congres al Asociației Chirurgilor „Nicolae Anestiadi” din Republica Moldova și cea de-a XXXIII-a Reuniune a Chirurgilor din Moldova „Iacomi-Răzeșu” 27-30 septembrie 2011Aims: To assess the effectiveness of intensive laparoscopic training on pigs during 10 years of training. Method: Between 2000 and 2010, 25 intensive (3 days) and 7 advanced (2 days) laparoscopic courses (gastric, biliary, colo-rectal and bariatric) on live tissue were organized, with 324 participants coming from 13 countries. This poster presents the effectiveness of the training of the 244 surgeons who followed the 3 days laparoscopy skills courses. At the beginning of the first day, during the training and at the end of each day the acquirement of the skills participants were evaluated. Three groups where studied: the first group with no experience in laparoscopic surgery; the second group with less than 10 laparoscopic cholecystectomy and the third group with more than 10 laparoscopic cholecystectomy. Results: The first group had a lot of difficulty and were able to acquire only less than 32% of the taught techniques, the second group performed better and acquired 62% of the taught techniques and the third group performed very well acquiring 95% of the taught techniques. Conclusion: Surgeons with no previous laparoscopic surgery experience take little benefit from these courses. They should be encouraged to acquire basic skills on trainer boxes or on virtual reality simulators before the training on pigs. Surgeons with very little experience in laparoscopic surgery acquire important skills, but the best benefit is taken by surgeons with some laparoscopic surgery experience

    Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study

    Get PDF
    Background: The diagnosis of symptomatic Alzheimer's disease is a clinical challenge in adults with Down syndrome. Blood biomarkers would be of particular clinical importance in this population. The astrocytic Glial Fibrillary Acidic Protein (GFAP) is a marker of astrogliosis associated with amyloid pathology, but its longitudinal changes, association with other biomarkers and cognitive performance have not been studied in individuals with Down syndrome. Methods: We performed a three-centre study of adults with Down syndrome, autosomal dominant Alzheimer's disease and euploid individuals enrolled in Hospital Sant Pau, Barcelona (Spain), Hospital Clinic, Barcelona (Spain) and Ludwig-Maximilians-UniversitĂ€t, Munich (Germany). Cerebrospinal fluid (CSF) and plasma GFAP concentrations were quantified using Simoa. A subset of participants had PET 18F-fluorodeoxyglucose, amyloid tracers and MRI measurements. Findings: This study included 997 individuals, 585 participants with Down syndrome, 61 Familial Alzheimer's disease mutation carriers and 351 euploid individuals along the Alzheimer's disease continuum, recruited between November 2008 and May 2022. Participants with Down syndrome were clinically classified at baseline as asymptomatic, prodromal Alzheimer's disease and Alzheimer's disease dementia. Plasma GFAP levels were significantly increased in prodromal and Alzheimer's disease dementia compared to asymptomatic individuals and increased in parallel to CSF AÎČ changes, ten years prior to amyloid PET positivity. Plasma GFAP presented the highest diagnostic performance to discriminate symptomatic from asymptomatic groups (AUC = 0.93, 95% CI 0.9−0.95) and its concentrations were significantly higher in progressors vs non-progressors (p < 0.001), showing an increase of 19.8% (11.8–33.0) per year in participants with dementia. Finally, plasma GFAP levels were highly correlated with cortical thinning and brain amyloid pathology. Interpretation: Our findings support the utility of plasma GFAP as a biomarker of Alzheimer's disease in adults with Down syndrome, with possible applications in clinical practice and clinical trials. Funding: AC Immune, La Caixa Foundation, Instituto de Salud Carlos III, National Institute on Aging, Wellcome Trust, JĂ©rĂŽme Lejeune Foundation, Medical Research Council, Alzheimer's Association, National Institute for Health Research, EU Joint Programme–Neurodegenerative Disease Research, Alzheimer's Society, Deutsche Forschungsgemeinschaft, Stiftung fĂŒr die Erforschung von Verhaltens, FundaciĂłn Tatiana PĂ©rez de GuzmĂĄn el Bueno & European Union's Horizon 2020 und UmwelteinflĂŒssen auf die menschliche Gesundheit

    High Distribution of CD40 and TRAF2 in Th40 T Cell Rafts Leads to Preferential Survival of this Auto-Aggressive Population in Autoimmunity

    Get PDF
    CD40-CD154 interactions have proven critical in autoimmunity, with the identification of CD4(lo)CD40(+) T cells (Th40 cells) as harboring an autoaggressive T cell population shedding new insights into those disease processes. Th40 cells are present at contained levels in non-autoimmune individuals but are significantly expanded in autoimmunity. Th40 cells are necessary and sufficient in transferring type 1 diabetes in mouse models. However, little is known about CD40 signaling in T cells and whether there are differences in that signaling and subsequent outcome depending on disease conditions. When CD40 is engaged, CD40 and TNF-receptor associated factors, TRAFs, become associated with lipid raft microdomains. Dysregulation of T cell homeostasis is emerging as a major contributor to autoimmune disease and thwarted apoptosis is key in breaking homeostasis.Cells were sorted into CD4(hi) and CD4(lo) (Th40 cells) then treated and assayed either as whole or fractionated cell lysates. Protein expression was assayed by western blot and Nf-kappaB DNA-binding activity by electrophoretic mobility shifts. We demonstrate here that autoimmune NOD Th40 cells have drastically exaggerated expression of CD40 on a per-cell-basis compared to non-autoimmune BALB/c. Immediately ex-vivo, untreated Th40 cells from NOD mice have high levels of CD40 and TRAF2 associated with the raft microdomain while Th40 cells from NOR and BALB/c mice do not. CD40 engagement of Th40 cells induces Nf-kappaB DNA-binding activity and anti-apoptotic Bcl-X(L) expression in all three mouse strains. However, only in NOD Th40 cells is anti-apoptotic cFLIP(p43) induced which leads to preferential survival and proliferation. Importantly, CD40 engagement rescues NOD Th40 cells from Fas-induced death.CD40 may act as a switch between life and death promoting signals and NOD Th40 cells are poised for survival via this switch. This may explain how they expand in autoimmunity to thwart T cell homeostasis

    Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort

    Get PDF
    BACKGROUND: Therapeutic trials are now underway in genetic forms of frontotemporal dementia (FTD) but clinical outcome measures are limited. The two most commonly used measures, the Clinical Dementia Rating (CDR)+National Alzheimer’s Disease Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD) and the FTD Rating Scale (FRS), have yet to be compared in detail in the genetic forms of FTD. METHODS: The CDR+NACC FTLD and FRS were assessed cross-sectionally in 725 consecutively recruited participants from the Genetic FTD Initiative: 457 mutation carriers (77 microtubule-associated protein tau (MAPT), 187 GRN, 193 C9orf72) and 268 family members without mutations (non-carrier control group). 231 mutation carriers (51 MAPT, 92 GRN, 88 C9orf72) and 145 non-carriers had available longitudinal data at a follow-up time point. RESULTS: Cross-sectionally, the mean FRS score was lower in all genetic groups compared with controls: GRN mutation carriers mean 83.4 (SD 27.0), MAPT mutation carriers 78.2 (28.8), C9orf72 mutation carriers 71.0 (34.0), controls 96.2 (7.7), p<0.001 for all comparisons, while the mean CDR+NACC FTLD Sum of Boxes was significantly higher in all genetic groups: GRN mutation carriers mean 2.6 (5.2), MAPT mutation carriers 3.2 (5.6), C9orf72 mutation carriers 4.2 (6.2), controls 0.2 (0.6), p<0.001 for all comparisons. Mean FRS score decreased and CDR+NACC FTLD Sum of Boxes increased with increasing disease severity within each individual genetic group. FRS and CDR+NACC FTLD Sum of Boxes scores were strongly negatively correlated across all mutation carriers (r_{s} =−0.77, p<0.001) and within each genetic group (r_{s} =−0.67 to −0.81, p<0.001 in each group). Nonetheless, discrepancies in disease staging were seen between the scales, and with each scale and clinician-judged symptomatic status. Longitudinally, annualised change in both FRS and CDR+NACC FTLD Sum of Boxes scores initially increased with disease severity level before decreasing in those with the most severe disease: controls −0.1 (6.0) for FRS, −0.1 (0.4) for CDR+NACC FTLD Sum of Boxes, asymptomatic mutation carriers −0.5 (8.2), 0.2 (0.9), prodromal disease −2.3 (9.9), 0.6 (2.7), mild disease −10.2 (18.6), 3.0 (4.1), moderate disease −9.6 (16.6), 4.4 (4.0), severe disease −2.7 (8.3), 1.7 (3.3). Sample sizes were calculated for a trial of prodromal mutation carriers: over 180 participants per arm would be needed to detect a moderate sized effect (30%) for both outcome measures, with sample sizes lower for the FRS. CONCLUSIONS: Both the FRS and CDR+NACC FTLD measure disease severity in genetic FTD mutation carriers throughout the timeline of their disease, although the FRS may be preferable as an outcome measure. However, neither address a number of key symptoms in the FTD spectrum, for example, motor and neuropsychiatric deficits, which future scales will need to incorporate
    • 

    corecore